Haixi Pharma adheres to the development philosophy of "Generics Empower Innovation, Innovation Drives the Future", and has launched R&D programs in therapeutic areas including oncology, Ophthalmology, endocrinology, psychiatry, cardiovascular, and gastroenterology.

For innovative drug development, we focus on developing small molecules drugs with clear medical needs and global market potential mainly in tumor immunotherapy,  Ophthalmology, immuno-related therapies, and metabolic disorders. We have established a small molecule innovative drug  R&D platform - MultiSel-Opt which enables a single drug molecule to selectively act on multiple protein targets for synergistic therapeutic mechanism. At the same time, the company makes full use of the abundant clinical trial resources in China, establishing cooperative relationships to advance clinical trial studies in humans in an effieient manner. The leading project, C019199, is about to enter Phase III clinical trials, with multiple trials in progress for different indications, both as monotherapy and in combination. The 2^nd project HXP056 is currently in Phase I/II clinical development, a potentially world’s first oral drug intended for the treatment of retinal diseases related to neovascularization, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Other projects in the pipeline are moving forward for IND (Clinical Trial) applications also in a timely manner.

For generic drugs, we focus on developing those first-to-market, difficult-to-duplicate and high-value generics. As of October 2025, 15 products have received marketing approval from the NMPA. Other products are under development at different stages, including laboratory research, process scale-up, and bioequivalent (BE) studies.

Patent Coverage

The company has put in a great deal of considerations in each of its innovative drug projects, constructing a multi-layered intellectual property protection throughout the R&D process. The strategy is to hold the IP position and render protection in every thinkable way for our innovative drugs in order to deter any imitators.

Industry-University-Research Collaboration

The company actively engages in university-enterprise cooperation with universities and serves as an internship base for Fuzhou University, Fujian Medical University, and Minjiang University, and also works closely with Peking University and Xiamen University, and other institutions for collaborations of scientific research.